Cadila gets USFDA nod to market arthritis drug

The group has now 88 approvals and has so far filed 216 ANDAs

Drug firm Cadila Healthcare today said it has received US health regulator's nod to market Etodolac extended release tablets, used in the treatment of arthritis, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to market Etodolac extended release tablets in strengths of 400mg, 500mg and 600 mg, Cadila Healthcare said in a filing to the BSE.

The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis, it added.

The group has now 88 approvals and has so far filed 216 abbreviated new drug applications (ANDAs).

Cadila scrip closed at Rs 809.15 on the BSE, down 0.25%.